Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of July 5, 2026, ABT trades at $95.40 with a market cap of $166.17B and a P/E ratio of 26.57. ABT moved +3.38% today. Year to date, ABT is -24.15%; over the trailing twelve months it is -28.86%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $117.75. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ABT insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $95.40 |
| Market Cap | $166.17B |
| P/E Ratio | 26.57 |
| EPS | $3.59 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $45.13B |
| Net Income | $6.28B |
| Gross Margin | 56.26% |
20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.75.